High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
AS Zayac, DJ Landsburg, ME Hughes… - Blood …, 2023 - ashpublications.org
In this multi-institutional retrospective study, we examined the characteristics and outcomes
of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a …
of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a …
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
JM Ribera, M Morgades, O Garcia-Calduch… - …, 2023 - pmc.ncbi.nlm.nih.gov
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly
effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) …
effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) …
[引用][C] CARMEN Regimen Shows Promise in MYC-Rearranged Aggressive Lymphoma.
J Goodmanhil - Cancer Therapy Advisor, 2023 - go.gale.com
The study included 68 patients, 22 of whom had high-grade B-cell lymphoma (HGBCL) and
46 of whom had Burkitt lymphoma (BL). In the HGBCL group, the median age was 55 years …
46 of whom had Burkitt lymphoma (BL). In the HGBCL group, the median age was 55 years …
[引用][C] Management of High-Grade B-Cell Lymphoma
AJ Olszewski - Clinical Lymphoma Myeloma and Leukemia, 2024 - Elsevier
[引用][C] Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
JM Ribera Santasusana, M Morgades… - 2024 - Ferrata Storti Foundation